Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics, Inc.

SAN FRANCISCO AND BOSTON, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED DATA FROM THE PHASE 2 APEX TRIAL OF APG777 FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS WAS ACCEPTED FOR A LATE-BREAKER ORAL PRESENTATION AT THE UPCOMING EADV CONGRESS 2025, TO BE HELD IN PARIS, FRANCE FROM SEPTEMBER 17-20, 2025. THE COMPANY WILL ALSO PRESENT MULTIPLE POSTER PRESENTATIONS HIGHLIGHTING APG777'S BEST-IN-CLASS POTENTIAL INCLUDING DATA SUPPORTING ITS COMBINATION STRATEGY.

APOGEE THERAPEUTICS ANNOUNCES LATE-BREAKER PRESENTATION OF 16-WEEK DATA FROM PHASE 2 APEX TRIAL OF APG777 FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS AT THE UPCOMING EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) 2025 CONGRESS

SAN FRANCISCO AND BOSTON, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE STIFEL 2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM ON TUESDAY, SEPTEMBER 16, 2025, AT 11:30 A.M. E.T.

APOGEE THERAPEUTICS TO PARTICIPATE AT THE STIFEL 2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM

POSITIVE 16-WEEK DATA FROM APEX PHASE 2 PART A MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS FOR APG777, A POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

APOGEE THERAPEUTICS PROVIDES PIPELINE PROGRESS AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

APEX PART A MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS AND EXCEEDED TRIAL OBJECTIVES, INCLUDING 7 1.0% DECREASE FROM BASELINE IN EASI AT WEEK 16

APOGEE THERAPEUTICS ANNOUNCES POSITIVE 16-WEEK DATA FROM PHASE 2 APEX CLINICAL TRIAL OF APG777, ITS POTENTIALLY BEST-IN-CLASS ANTI-IL-13 ANTIBODY, IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

SAN FRANCISCO AND BOSTON, JULY 06, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING NOVEL BIOLOGICS WITH THE POTENTIAL FOR DIFFERENTIATED EFFICACY AND DOSING IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, INCLUDING FOR THE TREATMENT OF ATOPIC DERMATITIS (AD), ASTHMA, EOSINOPHILIC ESOPHAGITIS (EOE), CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND OTHER I&I INDICATIONS, TODAY ANNOUNCED IT WILL REPORT PART A 16-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF APG777 ON MONDAY, JULY 7, 2025. FOLLOWING THE ANNOUNCEMENT, THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:00 A.M.

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT PART A 16-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF APG777 IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS ON JULY 7, 2025

SAN FRANCISCO AND BOSTON, MAY 29, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON THURSDAY, JUNE 5, 2025, AT 10:30 A.M. E.T.

APOGEE THERAPEUTICS TO PARTICIPATE AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

PHASE 2 APEX TRIAL OF APG777 IN ATOPIC DERMATITIS ADVANCING WITH INTERIM PART A 16-WEEK DATA EXPECTED IN MID-2025 AND PART B ACTIVELY ENROLLING

APOGEE THERAPEUTICS PROVIDES BUSINESS UPDATE, PIPELINE PROGRESS AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

MULTIPLE DOSES OF APG808 RESULTED IN RAPID SUPPRESSION OF FENO, A BIOMARKER OF TYPE 2 INFLAMMATION ASSOCIATED WITH EXACERBATIONS IN ASTHMA, WITH A ROBUST MAXIMAL FENO DECREASE FROM BASELINE OF 53%

APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM THE PHASE 1B TRIAL OF APG808, ITS NOVEL HALF-LIFE EXTENDED IL-4R ANTIBODY, IN PATIENTS WITH MILD-TO-MODERATE ASTHMA

SAN FRANCISCO AND BOSTON, MAY 01, 2025 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC., (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PRESENT AT THE BANK OF AMERICA HEALTH CARE CONFERENCE ON TUESDAY, MAY 13, 2025, AT 1:40 P.M. P.T. / 4:40 P.M. E.T.

APOGEE THERAPEUTICS TO PARTICIPATE AT THE BANK OF AMERICA 2025 HEALTH CARE CONFERENCE

ACCELERATED EXECUTION OF PHASE 2 APEX CLINICAL TRIAL FOR APG777, WITH PART A OVER-ENROLLED AND PART B INITIATED AHEAD OF SCHEDULE; TOPLINE PART A 16-WEEK DATA EXPECTED MID-2025

Apogee Therapeutics, Inc.

APGE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Apogee Therapeutics, Inc.

APGE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

APGE